REVIEW article
Front. Immunol.
Sec. Alloimmunity and Transplantation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1653344
This article is part of the Research TopicFinding New Hope in Old Treatments: Repurposing Immunotherapy in TransplantationView all 8 articles
Next generation targeted non-genotoxic conditioning for hematopoietic cell transplant and hematopoietic stem cell-based gene therapy
Provisionally accepted
- Emory University, Atlanta, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hematopoietic stem cell transplant (HSCT) and hematopoietic stem cell (HSC)-based gene therapy, including gene editing approaches, offer a promising strategy for addressing numerous lymphohematopoietic genetic defects. Although significant progress has been made since the first HSCT over 60 years ago, the widespread application of allogeneic HSCT and autologous gene therapy is still hindered by the need for pre-transplant conditioning. The eradication of host HSCs and their progeny is widely thought to be necessary to create "space" in the bone marrow niche and enable long term engraftment of transplanted cells. However, despite decades of research, alkylating agents such as busulfan, melphalan and treosulfan or total body irradiation still remain the backbone of most HSCT condidtioning regimens. These genotoxic conditioning agents are non-targeted and leave patients susceptible to infections, infertility, organ toxicities, and secondary malignancies. As a result, there is an urgent need to develop alternative, non-genotoxic conditioning regimens that can selectively deplete HSCs while sparing cells outside the lymphohematopoietic compartment. A growing body of preclinical and clinical breakthroughs demonstrate the effectiveness of monoclonal antibodies, antibody-drug conjugates, immunotoxins, radioimmunotherapy compounds, and even T cell redirection strategies for achieving targeted HSC elimination. The use of these new agents can transform HSCT, and in this review we aim to highlight the potential and limitations of next-generation, non-genotoxic or minimally toxic conditioning methods. These alternatives to conventional chemoradiation could reduce toxicity and improve the safety of HSC-based gene therapies, ultimately expanding patient access and eligibility for these transformative treatments.
Keywords: HSCT, Gene Therapy, Non-genotoxic, conditioning, Transplantation, HSC niche
Received: 24 Jun 2025; Accepted: 10 Sep 2025.
Copyright: © 2025 Okalova, Spencer and Chandrakasan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shanmuganathan Chandrakasan, shanmuganathan.chandrakasan@emory.edu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.